Authors
Latest:
Sponsored: The Evolving Role of Stem Cell Transplant in Older AML PatientsExperts discuss the phase III SIERRA trial, which recently demonstrated durable complete responses in patients with acute myeloid leukemia<br />
Latest:
Post–COVID-19 Infection Remains a Concern in Patients With CancerMany questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Latest:
Adjuvant Durvalumab Strategy in Locally Advanced Esophageal GEJ AdenocarcinomaHirva Mamdani, MD, explains the rationale for conducting a safety and efficacy study of durvalumab in patients following multimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma.
Latest:
Mutant-Specific Epidermal Growth Factor Receptor InhibitorsTreating sensitizing EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) leads to better outcomes compared with standard chemotherapy.
Latest:
Elacestrant + Targeted Therapy for ER+/HER2– Metastatic Breast Cancer: Early Phase Trial FindingsHope S. Rugo, MD, discusses the ELEVATE trial of elacestrant combined with various targeted therapies for patients with endocrine receptor-positive/HER2-negative metastatic breast cancer who have already received endocrine therapy and CDK4/6 inhibitors.
Latest:
Unmet Needs and Future Directions in Extensive-Stage SCLCHossein Borghaei, DO, shares insights regarding future directions and current unmet needs in extensive-stage small cell lung cancer. He provides advice to researchers about the importance of clinical trials in the setting of extensive-stage small cell lung cancer.
Latest:
Discussing Biomarkers and Best Options in NSCLCHossein Borghaei, MS, DO, provides an overview on his presentation given at the 18th Annual New York Lung Cancers Symposium.
Latest:
PD-L1 as a Biomarker Predictive of Response to Checkpoint Inhibition in Lung CancerA review of data regarding PD-L1 expression as a predictive biomarker of response to checkpoint inhibition in lung cancer.
Latest:
Novel Agents in Breast Cancer and Monoclonal AntibodiesHoward A. “Skip†Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.
Latest:
Dr. Howard A. Burris, III, on Modern Chemotherapy for Patients with HER2-Positive Breast CancerHoward A. "Skip" Burris, III, MD, president, Clinical Operations, chief medical officer and executive director of Drug Development, Sarah Cannon, talks about chemotherapy in the era of personalized medicine.
Latest:
The History of Metabolic Targets in Brain CancerHoward Fine, MD, director, Brain Tumor Center, Weill Cornell Medicine, discusses the history of metabolic targets in brain cancer.
Latest:
Findings From the COU-AA-302 TrialHoward I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial.
Latest:
Emerging Agents for T790M-Mutant Patients With NSCLCHoward L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses emerging agents on the horizon for patients with T790M-mutant patients with non-small cell lung cancer.
Latest:
Dr. Kaufman Discusses Durable Responses to Avelumab in Merkel Cell CarcinomaHoward L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.
Latest:
Dr. Sandler Discusses Docetaxel With Hormonal and Radiation Therapy in Patients With Prostate CancerHoward M. Sandler, MD, MS, FASTRO, Cedars Sinai, discusses patient benefit and toxicities of a phase III study of docetaxel with hormonal and radiation therapy of patients with prostate cancer.
Latest:
Efficacy of TAS-102 Continues to Hold Up in Metastatic CRC and Gastric CancersHoward S. Hochester, MD, discusses findings from the pooled safety analysis of TAS-102 in previously treated patients with colorectal cancer and gastric/gastroesophageal junction adenocarcinoma.
Latest:
TAS-102 Shows Similar Efficacy to 5-FU in Gastric/GEJ and Colorectal CancersHoward S. Hochster, MD, discusses the role of TAS-102 in patients with gastric/gastroesophageal junction or colorectal cancer in comparison to fluorouracil.
Latest:
Pembrolizumab Improves 5-Year Survival in Advanced NSCLC in KEYNOTE-001Hussain Borghaei, DO, MS, discusses the significance of the overall survival data update from the KEYNOTE-001 trial. This trial investigated the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced non–small cell lung cancer.
Latest:
Clinical Pearls on the Treatment of Metastatic and Unresectable MelanomaHussein Tawbi, MD, PhD, closes his discussion by sharing some clinical pearls for fellow oncologists treating patients with metastatic melanoma.
Latest:
Choosing Treatment Regimens in Patients with Triple-Negative Breast CancerHyman B. Muss, MD, professor of medicine, UNC Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill School of Medicine, discusses how he chooses which treatment to use for patients diagnosed with triple-negative breast cancer (TNBC).
Latest:
Combination of Veliparib and Chemotherapy in BRCA-Positive Breast CancerHyo Sook Han, MD, medical oncologist, Moffitt Cancer Center, discusses results of the phase II BROCADE trial, which evaluated the combination of the PARP inhibitor veliparib with carboplatin/paclitaxel in patients with <em>BRCA</em>-positive breast cancer.
Latest:
Interim Results for Gastric Cancer Treatment With Ramucirumab Plus PembrolizumabIan Chau, MD, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.
Latest:
Critical Unmet Needs in DLBCLIan Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.
Latest:
The Role of Olaratumab in SarcomaIan Judson, MD, medical oncologist, The Royal Marsden Hospital, discusses the future role of olaratumab in the treatment of patients with sarcoma.
Latest:
Deciding When to Use Polatuzumab + BR in R/R DLBCLIan W. Flinn, MD, PhD, discusses what factors go into his decision to use polatuzumab plus bendamustine and rituximab in certain patients with relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Integrating Molecular Pathology Into NSCLC Treatment SelectionIgnacio I. Wistuba, MD, Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, discusses how clinicians can best integrate molecular pathology into their treatment selection for patients with non-small cell lung cancer.
